← Human Trials & Peer-Reviewed Studies
Magnesium supplementation does not affect blood calcium level in treated hypoparathyroid patients.
Plain-language guide to PMID 22962426 (2012): pilot clinical trial of Vitamin D, K2, Magnesium and Zinc.
Key Facts
- PMID
- 22962426
- Journal
- The Journal of clinical endocrinology and metabolism
- Year
- 2012
- Study type
- Clinical Trial
- Authors
- Lubi M et al. (5 authors)
- DOI
- 10.1210/jc.2012-2301
What This Study Did, in Plain Language
What Was Tested
The paper reports a study of Vitamin D, K2, Magnesium and Zinc, published as a clinical trial.
The aim of this pilot study was to evaluate whether magnesium treatment affects plasma calcium levels in hypoparathyroid patients.
Why It Was Studied
The researchers have had two cases in their department in which treated hypoparathyroid patients with stable calcium levels developed hypercalcemia in conjunction with supplementary magnesium use.
To their knowledge, there has been no prospective study looking at the effect of supplementary magnesium on calcium homeostasis in hypoparathyroid patients.
Who Took Part
The age groups tagged for this paper are adults and middle-aged adults, both men and women.
The researchers conducted a prospective, two-phase, uncontrolled treatment trial at a referral center of endocrine disorders.
The researchers enrolled treated (calcium + vitamin D analog) hypoparathyroid patients with normal plasma magnesium levels.
How the Study Was Run
The researchers set it up as a pilot study.
It is described as a pilot, a small early test of whether a larger Vitamin D, K2, Magnesium and Zinc study would be practical.
What Was Measured
The researchers have had two cases in their department in which treated hypoparathyroid patients with stable calcium levels developed hypercalcemia in conjunction with supplementary magnesium use.
Topics PubMed links to this paper include Calcium, Creatinine, Dietary Supplements, Hypoparathyroidism, Magnesium and Phosphates.
What This Means in Plain Language
The paper is a pilot study of Vitamin D, K2, Magnesium and Zinc.
Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.
The publication is from 2012 (The Journal of clinical endocrinology and metabolism), a journal based in United States.
More context: the Vitamin D, K2, Magnesium and Zinc compound page, all human trials.
Our Notes on the Compound
Vitamin D, K2, Magnesium and Zinc: Magnesium is described as required for AMPK to function.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.